Cabozantinib (XL184), targeting VEGFR1/2, MET, RET, KIT and FLT3, has been assessed in several cell line models and has been approved by the FDA for the treatment of progressive medullary thyroid cancer [53]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.